Glucosylceramide synthase inhibitors

US11008316B2 · kind B2 · utility

Assignee

• Genzyme Corporation · US

Inventors

• Elyse Bourque · Langley, CA
• Mario CABRERA-SALAZAR · Watertown, US
• Cassandra Celatka · Hull, US
• Seng H. Cheng · Wellesley, US
• Bradford H. Hirth · Framingham, US
• Andrew C. Good · Wallingford, US
• Katherine JANCSICS · Wilmington, US
• John Marshall · Milford, US
• Markus Metz · Bellevue, US
• Ronald K. Scheule · Hopkinton, US
• Renato Skerlj · Vancouver, CA
• Yibin Xiang · Dracut, US
• Zhong Zhao · Munich, DE
• John Leonard · Manchester, US
• Thomas A. Natoli · Revere, US
• Elina Makino · Winchester, US
• Herve Husson · Boston, US
• Oxana Beskrovnaya · Southborough, US

Key dates

• Filing date: Apr 18, 2017
• Grant date: May 18, 2021
• Expiry date: Apr 18, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to inhibitors of glucosylceramide synthase (GCS), such as Compound of Formula I, shown below, as defined herein, useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.